Given the converging role of NMT1 in AMPK and the Src pathway, for ovarian cancers prone to metastasis or drug resistance, the combination of NMT1 inhibitors and existing drugs may provide a new therapeutic avenue. Here, SRC is linked to ovarian carcinoma.